Richard F Bergstrom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10916160/publications.pdf

Version: 2024-02-01

29 papers

2,023 citations

279798 23 h-index 477307 29 g-index

29 all docs 29 docs citations

times ranked

29

1399 citing authors

#	Article	IF	CITATIONS
1	Olanzapine. Clinical Pharmacokinetics, 1999, 37, 177-193.	3.5	460
2	Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia. American Journal of Psychiatry, 2010, 167, 181-189.	7.2	181
3	Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clinical Pharmacology and Therapeutics, 1992, 51, 239-248.	4.7	171
4	The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clinical Pharmacology and Therapeutics, 1988, 43, 412-419.	4.7	117
5	Fluoxetine in Depressed Patients on Dialysis. International Journal of Psychiatry in Medicine, 1997, 27, 71-80.	1.8	114
6	Fluoxetine kinetics and protein binding in normal and impaired renal function. Clinical Pharmacology and Therapeutics, 1984, 36, 138-144.	4.7	104
7	Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry, 2010, 10, 45.	2.6	76
8	Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 278-283.	1.4	75
9	High-performance liquid chromatographic determination of penicillamine in whole blood, plasma, and urine. Biomedical Applications, 1981, 222, 445-452.	1.7	70
10	Fluoxetine disposition and elimination in cirrhosis. Clinical Pharmacology and Therapeutics, 1988, 44, 353-359.	4.7	69
11	Penicillamine kinetics in normal subjects. Clinical Pharmacology and Therapeutics, 1981, 30, 404-413.	4.7	67
12	Olanzapine Pharmacokinetics in Pediatric and Adolescent Inpatients With Childhood-Onset Schizophrenia. Journal of Clinical Psychopharmacology, 2000, 20, 220-225.	1.4	64
13	The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clinical Pharmacology and Therapeutics, 1997, 62, 145-156.	4.7	63
14	Intravenous nizatidine kinetics and acid suppression. Clinical Pharmacology and Therapeutics, 1985, 37, 162-165.	4.7	40
15	Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanol. Clinical Pharmacology and Therapeutics, 1985, 37, 658-664.	4.7	38
16	Pharmacokinetics of olanzapine long-acting injection. International Clinical Psychopharmacology, 2014, 29, 299-312.	1.7	37
17	Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning Techniques. Clinical and Translational Science, 2019, 12, 519-528.	3.1	37
18	Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clinical Pharmacology and Therapeutics, 1997, 62, 643-651.	4.7	36

#	Article	IF	CITATION
19	The in vitro loss of penicillamine in plasma, albumin solutions, and whole blood: Implications for pharmacokinetic studies of penicillamine. Life Sciences, 1980, 27, 189-198.	4.3	30
20	Absorption studies of the H2-blocker nizatidine. Clinical Pharmacology and Therapeutics, 1987, 42, 514-520.	4.7	29
21	Nizatidine disposition in subjects with normal and impaired renal function. Clinical Pharmacology and Therapeutics, 1988, 43, 688-695.	4.7	25
22	Secretion of nizatidine into human breast milk after single and multiple doses. Clinical Pharmacology and Therapeutics, 1990, 47, 724-730.	4.7	25
23	Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. British Journal of Clinical Pharmacology, 2003, 56, 184-187.	2.4	24
24	Oral Olanzapine Disposition in Adolescents with Schizophrenia or Bipolar I Disorder. Paediatric Drugs, 2010, 12, 201-211.	3.1	20
25	Nizatidine, an H ₂ â€Receptor Antagonist: Disposition and Safety in the Elderly. Journal of Clinical Pharmacology, 1987, 27, 618-624.	2.0	19
26	The pharmacokinetics of penicillamine in a female mongrel dog. Journal of Pharmacokinetics and Pharmacodynamics, 1981, 9, 603-621.	0.6	16
27	Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion. Clinical Pharmacology and Therapeutics, 1990, 47, 499-503.	4.7	8
28	Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials. Clinical and Translational Science, 2021, 14, 1864-1874.	3.1	5
29	Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for Onâ€Demand HIV Preexposure Prophylaxis. Clinical Pharmacology and Therapeutics,	4.7	3